LLY vs PRAX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Praxis Precision Medicines, with its current $7.43B market cap, demonstrates significant progress in its clinical pipeline since its '0/10' historical score. The company is advancing late-stage assets targeting large, underserved CNS markets, notably PRAX-118 (Essential Tremor, with NDA submission by year-end 2025) and PRAX-562 (severe epilepsies, progressing to Phase 3). This pipeline strength, c...